1987 Novartis AGNovartis Beijing, founded by and
Beijing Pharmaceutical group and Beijing Zizhu Pharmaceuticals,
is the first foreign pharmaceutical company in China.
seems to accumulate mutations slowly; even so, variants might pose a challenge
for a vaccine.
Sinovac researchers mixed antibodies taken from monkeys,
rats, and mice given their vaccine with strains of the virus isolated from
COVID-19 patients in China, Italy, Switzerland, Spain, and the UK.
Novartis Beijing founded by and Beijing Pharmaceutical group and Beijing Zizhu
1989 The Pfizer Dalian facility,
built jointly with Dalian Pharmaceuticals is the first to get
certification in China.
1993 Eli Lilly returns to
1994 Merck set up its first
joint venture in China.
Bayer invests in world-class
facilities in an integrated production site in the Shanghai Chemical
Shanghai Schering-Plough Pharmaceutical
Co., Ltd is a joint-venture with Shanghai Pharmaceutical Industry
Corporation and Shanghai Corporation of Pharmaceutical Economic and
Technical International Coöperation.
Eisai is the first
manufacturer among the US, European and Japanese PHRMA firms to manufacture in
China via a 100% owned subsidiary.
Boehringer Ingelheim enters Chinese market in and
invested $25 million in a new facility in Shanghai in 2002.
Marion russell establisha a head offices in Beijing to manage operations in
mainland China and Hong Kong.
There are 5,501 kidney transplants performed in China, second
only to the number in the US (13,372).
Sales of immunosuppressant drugs
are relatively high.
AstraZeneca establishes its largest site in Asia in Wuxi.
Boehringer Ingelheim invest $25 million in a Shanghai
Anti-coagulant Novastan (argatroban) launched in
launches a medical 'education' campaign targeting 3,500 doctors in 20 Chinese
November 19, 2008
foreign office of the FDA
opens in Beijing with three agents.
1800 foreign funded pharmaceutical enterprises in
The top 20 pharmaceutical
companies set up joint ventures in China.
Market conditions are
challenging with competition at an
Pfizer produces and markets
more than 40 drugs in China.
Pfizer has manufacturing facilities
in Dalian, Suzhou and Wuxi.
GlaxoSmithKline with 2000
employees in China is sold in 60
sells drugs treating HIV, asthma and infection.
Merck sells antibiotics
prostate drugs, cardiovascular
drugs, pain relievers,
Novartis has four manufacturing
facilities in Beijing and Shanghai.
Novartis core businesses
involve patented drugs,
generic drugs, eye protection drugs
and health products.
German-French company, sells several drugs in China.
AstraZeneca, Shanghai headquarter, 25
AstraZeneca sells several
products, including the atypical antiPsychotic
used in the management of schizophrenia and
Seroquel (quetiapine) and Nexium (esomeprazole).
AstraZeneca has nearly 3,000 employees working in manufacturing, sales,
clinical research and
new product development.
AstraZeneca in over 110 targeted
cities, with 800 marketing
was one of the earliest to enter Chinese market.
Johnson & Johnson has established
subsidiaries which include Shanghai Johnson & Johnson Pharmaceuticals,
Ltd, Johnson & Johnson Medical (Shanghai) Ltd, Johnson &
Johnson Medical (China) Ltd, Johnson & Johnson (China) Ltd,
Johnson & Johnson (China) Investment Co., Ltd, manufacturing and
selling drugs in China.
Wyeth best-seller in China
the recognized leader in biotech, genomics and gene therapy.
Operations, in Hong Kong, Taiwan, and China are led by management
holding companies, with subgroups and production joint ventures operating
independently under the strategic direction of Bayer.
Bayer has production facilities
on stream in all corporately active business lines. Chinese production accounts
for an increasing proportion of profit margins.
Bayer is engaged
in a number of coöperation projects with some of the foremost research
institutes and universities in China, to conduct research in the field of
innovative materials, health care and crop
Bayer coöperates with the Chinese Academy of
Science and affiliated institutes such as the Institute of Materia
Medica and the Kunming Institute of Botany in Yunnan with the aim to
identify new compounds in the healthcare and crop science field.
Bayer supports a number of research chairs at Chinese
universities; Tsinghua-Bayer Public Health and HIV/AIDS Media Studies
Program, a national platform designed to play a key role in China's public
Bayer HealthCare supports a chair for Healthcare
Management at the China European International Business School (CEIBS) in
Its drugs treating
diseases and cardiovascular diseases are
established in Chinese pharmaceutical markets.
russell joint ventures; Hoechst Huabei Pharmaceuticals Ltd in
Shijiazhuang, a heartland of the Chinese pharmaceutical industry, and
Hoechst Shanghai International Pharmaceuticals Ltd.
Eli Lilly main
facility is in Suzhou, Jiangsu province and main products include cipro,
insulin, and erectile
Abbott Laboratories Ltd sells
a series of products including
ventures in China, Xian-Janssen Pharmaceutical's success includes a
range of high-volume medicines to treat gastronintestinal problems, fungi,
allergies and pain, as well as psychosis
Paul Janssen's decision to enter China early,
to invest inland, and to keep investment plans moving
along in the wake of 1989 Tiananmen Square event have helped build good
relations with the Chinese government. Paul Appermont and Joos Horsten lead the
Xian-Janssen Pharmaceutical project.
Degussa is shifting
a large proportion of its pharmaceutical chemicals production to China to take
advantage of low-cost manufacturing.
Degussa restructure of
facilities, the vast majority in Germany, resulting in the transfer of the
manufacture of other products.
Rhodia is improving its
competitive position in analgesics by making a major investment in its Wuxi,
China acetaminophen (paracetamol) production facility and consolidating its
North American and European operations.
Rhodia shuttered its
Luling, Louisiana, paracetamol operations in 2004 and consolidated production
in Roussillon, France and Wuxi, China.
Paracetamol production capacity
is adjusted to match consumption levels.
Acetaminophen linked to autism?
Acetaminophen Linked to Lower Empathy Levels
Acetaminophen use in pregnancy linked to kids' behavioral
Mechanisms of Acetaminophen-Induced Liver Necrosis
11 Million Bottles Possibly Tainted With Metal
Sankyo is manufacturing the hyperlipemic
Mevalotin (pravastatin), anti-inflammatory Loxonin (loxoprofen),
antibiotic Banan (cephalosporin antibiotic) and hypertensive
Olmesartan (angiotensin II receptor antagonists).
is manufacturing and marketing all four global products - thiazolidinedione
with hypoglycemic action Actos (pioglitazone); anti-ulcer proton pump
inhibitor Takepron (lansoprazole); gonadotropin-releasing hormone
agonist cancer drug Leuplin (leuprolide acetate); and hypertensive
Yamanouchi is manufacturing and
marketing anti-ulcer histamine H2-receptor antagonist Gaster
(famotidine); urinary impediment treatment Harnal (tamsulosin); a
selective alpha blocker used in the symptomatic treatment of benign prostatic
hyperplasia and hypertensive calcium channel blocker Hypoca. There are
plans to launch Dolner for peripheral circulation and anti-emetic
Daiichi mainly sells synthetic antibacterials
Cravit (oral and injectable levofloxacin) and Tarivid
(ofloxacin). It originally planned to launch neurotransmission enhancer
Translon too, but after development was halted in Japan, development in
China also ended. Sales are behind plan chiefly due to the suspension of
Translon's development and the proliferation of generic and copycat
versions of Cravit.
Tanabe markets hypertensive
Herbesser(diltiazem hydrochloride) and Tanatril (imidapril
The China subsidiary Kuangchou Green Cross of
Mitsubishi Pharma has been extending transfusion business
(manufacturing, sales) since the days of the former Green Cross.
Mitsubishi Pharma sold its transfusion business in Japan to Otsuka
Pharmaceutical as part of a restructuring.
Prograf(tacrolimus or fujimycin) is being marketed in China by a
Fujisawa subsidiary - potential is significant due to the ever
increasing number of organ transplants.
The top 30 drugs by sales in
China (hospital market base) included two such drugs: Novartis'
immunosuppressant drug used in post-allogeneic organ transplantNeoral
(cyclosporine) and Roche's immunosuppressant drug used to prevent
rejection in organ transplantation CellCept (mycophenolate mofetil).
Chugai exports white blood cell production stimulant
Neutrogin (lenograstim) to China.
colony-stimulating factor is marketed in China.
its manufacturing and marketing operations in China and Asia earlier than in
the European and US markets.
two global products, anti-ulcer proton pump inhibitors
acetylcholinesterase inhibitor treatment Aricept(donepezil), and adds
Kyowa Hakko has exported cancer
drugs and plans to market the hypertensive dihydropyridine calcium channel
blockerConiel(benidipine) and anti-allergy antihistamine and mast cell
stabilizer Allelock(olopatadine hydrochloride).
makes and sells health drinks (tonics) in China, but has no specific plans for
prescription medications. The rights to macrolide antibiotic
Clarith/Biaxin(clarithromycin) outside Japan are licensed to
Terumo is using China as a manufacturing base
making products for the US and European and Japanese markets. Terumo is
in the process of exploring China as a market.
McNeil Consumer Healthcare, a division of
Johnson & Johnson, announced
the recall of several hundred batches of
medicines, including Benadryl, Motrin, Rolaids, Simply Sleep, St. Joseph
Aspirin and Tylenol.
The response was anything but swift.
recall came 20 months after McNeil first began receiving consumer complaints
about moldy-smelling bottles of Tylenol Arthritis Relief
Johnson & Johnson did not conduct a timely, comprehensive
investigation, did not quickly identify the source of the problem, and did not
notify authorities in a timely
fashion thus prolonging consumer exposure to the products.
This web site is not a commercial web site and
is presented for educational
This website defines a
new perspective with which to engage reality to which its author adheres. The
author feels that the falsification of reality outside personal experience has
forged a populace unable to discern propaganda from
reality and that this has been done purposefully by an international
corporate cartel through their agents who wish to foist a corrupt version of
reality on the human race. Religious intolerance occurs
when any group refuses to tolerate religious practices, religious beliefs or
persons due to their religious ideology. This web site marks the founding of a
system of philosophy named The Truth of the Way of the Lumière Infinie -
a rational gnostic mystery religion based on reason which requires no leap of
faith, accepts no tithes, has no supreme leader, no church buildings and in
which each and every individual is encouraged to develop a personal relation
with the Creator and Sustainer through the pursuit of the knowledge of reality
in the hope of curing the spiritual corruption that has enveloped the human
spirit. The tenets of The Truth of the Way of the Lumière Infinie are
spelled out in detail on this web site by the author. Violent acts against
individuals due to their religious beliefs in America is considered a "hate
This web site in no way condones violence. To the contrary the
intent here is to reduce the violence that is already occurring due to the
international corporate cartels desire to control the human race. The
international corporate cartel
already controls the world economic system, corporate media worldwide, the
global industrial military entertainment complex and is responsible for the
collapse of morals, the elevation of self-centered behavior and the destruction
of global ecosystems. Civilization is based on coöperation.
Coöperation does not occur at the
point of a
American social mores and values have declined precipitously
over the last century as the corrupt international cartel has garnered more and
more power. This power rests in the ability to deceive the populace in general
through corporate media by pressing emotional buttons which have been
preprogrammed into the population through prior mass media psychological
operations. The results have been the destruction of the family and the
destruction of social structures that do not adhere to the corrupt
international elites vision of a
perfect world. Through distraction and coercion the direction of thought of
the bulk of the population has been directed toward solutions proposed by the
corrupt international elite that further consolidates their power and which
further their purposes.
All views and opinions presented on this web
site are the views and opinions of individual human men and women that, through
their writings, showed the capacity for intelligent, reasonable, rational,
insightful and unpopular thought. All factual information presented on this web
site is believed to be true and accurate and is presented as originally
presented in print media which may or may not have originally presented the
facts truthfully. Opinion and thoughts
have been adapted, edited, corrected, redacted, combined, added to, re-edited
and re-corrected as nearly all opinion and thought has been throughout time but
has been done so in the spirit of the original writer with the intent of making
his or her thoughts and opinions clearer and relevant to the reader in the
Fair Use Notice
This site may contain
copyrighted material the use of which has not always been specifically
authorized by the copyright owner. We are making such material available in our
efforts to advance understanding of criminal justice,
political, economic, democratic, scientific, and social justice issues, etc. We
believe this constitutes a 'fair use' of any such copyrighted material as
provided for in section 107 of the US Copyright Law. In accordance with Title
17 U.S.C. Section 107, the material on this site is distributed without profit
to those who have expressed a prior interest in receiving the included
information for research and educational purposes. For more information see:
www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted
material from this site for purposes of your own that go beyond 'fair use', you
must obtain permission from the copyright owner.
© Lawrence Turner
All Rights Reserved